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Abstract
Cancer progression largely depends on tumor blood vessels as well on immune cell infiltration. In various tumors, vascular cells,
namely endothelial cells (ECs) and pericytes, strongly regulate leukocyte infiltration into tumors and immune cell activation,
hence the immune response to cancers. Recently, a lot of compelling studies unraveled the molecular mechanisms by which
tumor vascular cells regulate monocyte and tumor-associated macrophage (TAM) recruitment and phenotype, and consequently
tumor progression. Reciprocally, TAMs and monocytes strongly modulate tumor blood vessel and tumor lymphatic vessel
formation by exerting pro-angiogenic and lymphangiogenic effects, respectively. Finally, the interaction between monocytes/
TAMs and vascular cells is also impacting several steps of the spread of cancer cells throughout the body, a process called
metastasis. In this review, the impact of the bi-directional dialog between blood vascular cells and monocytes/TAMs in the
regulation of tumor progression is discussed. All together, these data led to the design of combinations of anti-angiogenic and
immunotherapy targeting TAMs/monocyte whose effects are briefly discussed in the last part of this review.
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1 Introduction
1.1 Tumor-associated macrophages
1.1.1 TAMs in the tumor microenvironment
Tumor-associated macrophages (TAMs) are major tumor
microenvironment (TME) cells and represent an important
part of the cancer immune infiltrate. TAM infiltration and
TAM numbers are correlated with poor prognosis in a ma-
jority of cancer types [1]. TAMs play an important role in
cancer development notably via the promotion of tumor
g r ow t h , t umo r i n f l amma t i o n , a n g i o g e n e s i s ,
lymphangiogenesis, metastasis, immunosuppression, and
chemotherapeutic resistance [2–5]. Macrophages are clas-
sified as pro-inflammatory M1 macrophages and anti-
inflammatory M2 macrophages. This classification is
oversimplified since TAMs can express both M1 and M2
markers, and hence, TAMs are classified onto a M1 and M2
polarization axis in which M1 and M2 macrophages are the
two extremes. Basically, and based on in vitro experiments,
M1 macrophages are polarized with pro-inflammatory cy-
tokines and bacterial molecules such as interferon γ and
lipopolysaccharides. M1 macrophages express high levels
of pro-inflammatory cytokines (e.g., IL-12, tumor necrosis
factor α (TNFα), and IL-6) and intracellular host response
genes (e.g., CD80 and IFIT1) [6, 7]. M2 macrophages are
divided into at least three subsets called M2a, M2b, and
M2c. This M2 classification in three subsets was firstly pro-
posed in [6]. M2a are activated by IL-4 and/or IL-13 and
express high levels of CD206, CD163, and fibronectin [6,
7]. M2b are induced by Toll-like receptors ligands and im-
mune complex activation, whereas M2c are activated by IL-
10. Interestingly, macrophage M2 polarization is also in-
duced by the TME [8–14]. Nonetheless, the three classes
of M2 macrophages share common features such as IL-
12low and IL-10high and arginase-1 (Arg-1)high, whereas
M1 macrophages are IL-12high, IL-23high, and IL-10low. In
the TME, CD163 and CD206 are commonly used to identify
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1.1.2 Origins of TAMs
There exist at least two origins of TAMs. TAMs can originate
either from tissue-resident macrophages (TRMs) or from
blood vessel inflammatory monocytes (IMs) CCR2+, which
are recruited via CCL2 chemotaxis [15–17]. TRMs are present
in healthy tissues, hence before cancer initiation [15]. TRMs
arise from embryonic progenitor–derived macrophages (e.g.,
brain macrophages also called microglia) or from blood
monocytes (e.g., intestine or dermis). Furthermore, TRMs
are able to self-maintain without adult blood monocyte con-
tribution. Although TRMs are known for a while, the impli-
cation of TRMs in cancers has only recently been investigat-
ed, mostly in murine tumor models. For example, TRMs pro-
mote pancreatic ductal adenocarcinoma (PDAC) progression
[18]. Indeed, colony-stimulating factor 1 (CSF1) antibodies
combined with clodronate liposome followed by 10 days of
blood monocyte recovery induce an almost complete TRM
depletion without affecting circulating monocyte. In these
conditions, tumor burden and high-grade carcinoma develop-
ment are drastically reduced [18]. Nonetheless, monocyte-
derived macrophages represent the major macrophage popu-
lation in a majority of murine cancer types, such as breast,
lung, brain, and hepatocellular carcinoma [15]. Monocytes
are classified into 3 subsets in humans and in mice, according
to marker expression [19, 20]. There are IMs (CD16−/CD14+/
CX3CR1
lo in human, Ly6Chigh/CD43lo/CX3CR1lo in mouse),
non-classical monocytes (or patrolling, CX3CR1high, CD14lo,
CD16+ in human and Ly6Clo/CD43high/CX3CR1high in
mouse), and intermediate monocytes (CX3CR1high, CD14+,
CD16+ in human, Ly6CintCD43hiCX3CR1hi in mouse).
Numerous murine studies showed that IMs are the major
source of TAMs in tumors, such asmammary tumors and their
associated lung metastases, hepatocellular carcinoma,
orthotopic Lewis lung carcinoma (LLc), and PDAC [19].
Furthermore, IMs display pro-tumoral functions such as an-
giogenesis and metastasis promotion [19]. Non-classical and
intermediate monocytes have pro and anti-tumoral functions.
Indeed, human intermediate and non-classical CD16+ mono-
cytes promote angiogenesis in vitro [21] and murine Ly6Glo
patrolling monocytes are immunosuppressive in vivo [22, 23],
whereas murine patrolling monocytes prevent breast to lung
metastasis in murine PyMT breast cancer model [24]. Another
type of monocyte classification exists, based on the receptor
tyrosine kinase Tie2 expression. Indeed, recently, Tie2-
expressing monocytes (TEMs) have been discovered by De
Palma and colleagues [25, 26]. Before these studies, only ECs
were thought to express the angiopoietin (1–4) receptor Tie2
[25]. Nowadays, some cell types have been discovered to
express Tie2: endothelial cells (ECs), TEMs, a subset of
TAMs, pericyte precursors of mesenchymal origin, a subset
of hematopoietic stem cells, and some cancer cell lines
[26–28]. Two studies showed that Tie2 is expressed mainly
by intermediate monocyte (CD14+ CD16+), whereas one
study shows that Tie2 is also expressed in non-classical mono-
cyte (CD14dim CD16+). Hence, Tie2 is expressed mostly but
not exclusively in CD16+ monocytes and to a lesser extent in
CD16− monocytes [29].
1.2 Tumor blood vessels
1.2.1 The onset of angiogenesis or the “angiogenic switch”
During cancer development, the transition from an avascular
tumor to a vascularized tumor, called the “angiogenic switch”
is a critical step [30, 31]. This switch occurs when the balance
between pro-angiogenic factors (e.g., vascular endothelial
growth factor (VEGF)-A) and anti-angiogenic factors (e.g.,
statins) shifts towards angiogenesis [30]. This switch appears
during the progression from hyperplasia to neoplasia and co-
incides with malignant transition in PyMT and RIP1-Tag2
mice models. It is needed for malignant tumor progression
[32, 33]. Immune cells such as TAMs and neutrophils are
involved in this process. For example, in the PyMT murine
breast cancer model, high TAM infiltration precedes the onset
of angiogenesis. Furthermore, vasculature development is ob-
served earlier in this model when macrophage infiltration is
induced with CSF1 transgenic overexpression specifically in
mammary tissues [32]. In the Rip1-Tag2 mouse pancreatic
tumor model, neutrophil ablation with anti-Gr1 antibody
strongly diminishes tumor vessel development [34].
1.2.2 Lymphatic vasculature and lymphangiogenesis
Lymphatic vasculature is critically involved in fluid homeo-
stasis regulation, immune cell dissemination/surveillance, and
lipid reabsorption. Absence or non-functional lymphatic sys-
tem causes lymphedema, a disease characterized by huge
swelling and repeated skin infections.
Lymphangiogenesis is defined as the formation of new
lymphatic vessels from existing ones. It occurs during embry-
onic development and during tumor growth. It is correlated
with a bad prognosis in cancer [35]. Lymphatic vessel
hyaluronic receptor 1 (LYVE 1), podoplanin, and prospero
homeobox 1 (prox1) are lymphatic EC (LEC) markers.
Mechanistically, VEGF-C and VEGF-D are the two main
lymphangiogenic factors which promote lymphangiogenesis
by activating LECs VEGF receptor 3 (VEGFR-3) [5].
Lymphatic vasculature is critically involved in the metastatic
spread of cancer cells into lymph nodes and finally to distant
organs [36–39]. Lymphatic vessel density and lymph node
status (i.e., the presence or the absence of cancer cells) is
associated with poor prognosis and metastasis in several can-
cers [35]. The link between VEGF-C, VEGF-D, lymphatic
vessel density, lymph node metastasis, and prognosis is exten-
sively reviewed in [40].
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1.2.3 Tumor blood vessels and immune system: endothelial
anergy
During cancer progression, the immune system is progressively
modified by the TME in a process called immunoediting. This
process is composed of three phases, namely elimination, equi-
librium, and escape. In the two first phases, the immune system
is able to kill cancer cells notably via CD8+ T cells and natural
killer (NK) cells. During these stages, TAMs belong mostly to
M1 phenotype and are able to kill cancer cells and to activate
the immune system. For example, in early-stage human lung
tumors, TAMs mostly share both M1 and M2 markers and are
able to activate T cell function, and hence are anti-tumoral [41].
In pancreatic pre-cancerous lesions, in gastrointestinal stromal
tumors, in ovarian cancer, and in bladder cancer, TAMs mostly
belong to the M1 phenotype and are progressively skewed to-
ward the M2 phenotype during disease progression [42–44]. In
later stages, TAMs display mostly M2 phenotype and are pro-
tumoral and immunosuppressive.
Tumor blood vessels constitute a barrier regulating im-
mune cell recruitment from blood into tumor via extravasa-
tion. The regulation of immune cell extravasation into tumor
through blood vessels is then crucial in the regulation of tumor
progression. This process is highly regulated and is composed
of several steps. First, there is leukocyte rolling followed by
the arrest and firm adhesion to ECs. Then, leukocytes trans-
migrate through ECs to extravasate and infiltrate the tissue.
This process requires adhesion molecules expressed by ECs
such as E-selectin (rolling), ICAM1 and VCAM1 (firm ar-
rest), and VE-cadherin and CD31 (transendothelial migration)
[45]. The expression of these proteins is tightly regulated and
promoted by inflammatory stimuli such as TNFα. Tumor ves-
sels are modified by TME to induce endothelial anergy, nota-
bly via VEGF [46]. In this state, tumor endothelial cells are
unresponsive to pro-inflammatory stimuli such as TNFα and
hence do not promote anymore leukocyte extravasation [47].
This anergy is crucial in tumor growth promotion, likely more
importantly during the elimination and equilibrium phases,
because the immune system is anti-tumoral. For example,
the overexpression of EGF-like domain–containing protein 7
(Egfl7) in cancer cells, an endothelial activation repressor
[48], promotes tumor growth and development by preventing
leukocyte infiltration via endothelial E-selectin and ICAM1
and VCAM1 adhesion molecule repression [49].
Tumor blood and lymphatic vessels also modulate the im-
mune system (this is well reviewed in [46]). Indeed, lymphatic
ECs (LECs) and ECs both express program death-ligand 1
(PD-L1), which inhibits T cell function [50, 51].
Furthermore, ECs can induce T cell apoptosis by Fas ligand
expression [52]. Tumor ECs are modified by the TME.
Indeed, IL-6 and IL-10 secretion from lung tumor ECs is
strongly increased. Normal lung ECs induce strong NK cell
activation, whereas this ability is strongly reduced in ECs
from lung tumors [53]. Furthermore, IL-6 and IL-10 cytokines
are involved in macrophage polarization towards M2 pheno-
type and hence promote tumor growth [54, 55].
To recapitulate, tumor blood vessels regulate immune cell
infiltration as well as their activation in tumors. In this review,
the impact of vascular cells (ECs and pericytes) on monocyte
and TAM recruitment into tumors will be discussed.
Furthermore, the impact of vascular cells on monocyte and
TAM angiogenic phenotype and polarization will also be de-
scribed. Reciprocally, the impact of TAMs, TEMs, and clas-
sical and non-classical monocytes on blood vessels will be
emp h a s i z e d . T h e i r im p a c t o n a n g i o g e n e s i s ,
lymphangiogenesis, and metastasis will be detailed.
2 Effects of vascular and perivascular cells
on macrophages (related to Fig. 1)
2.1 Monocyte and macrophage recruitment by ECs
and pericytes (related to Fig. 1a)
TAM recruitment in cancer is involved in the angiogenic
switch induction; promotes tumor growth, metastasis, vessel
“abnormalization”; and is associated with a bad prognosis in
most cancer types. Indeed, macrophage depletion by different
ways has a negative impact on these features. TAMs are re-
cruited by different chemokines and cytokines such as chemo-
kine (C-C motif) ligand 2 (CCL2), CCL5, CCL7,
angiopoietin-2 (Ang-2), CSF1, VEGF, IL-33, semaphorin
3D, endothelial monocyte–activating polypeptide-II (EMAP-
II), endothelin (ET)-1 and 2, stromal cell–derived factor 1α
(SDF1α/CXCL12), eotaxin, and oncostatin which are secret-
ed by cancer cells, stromal cells, and perivascular and vascular
cells. This is extensively reviewed in [69, 70]. TAMs are
classified not only according to their marker expression into
M1 or M2 phenotype, but also according to their tumor local-
ization into migratory TAMs or perivascular TAMs [4, 17].
Here, we will focus on the effects of ECs and perivascular
cells on TAM and monocyte recruitment as well as on their
localization within the tumor.
2.1.1 EC-derived angiopoietin-2 (Ang-2)
Ang-2 is mainly released by ECs in tumors, but in some cases,
Ang-2 is also expressed by cancer cells [71]. Ang-2 is stored
in Weibel-Palade bodies in ECs [72, 73], and its expression
and release from EC are regulated by CTHRC1/ERK/AP-1
signaling and by neuroligin 2 [74, 75]. In vitro, EC-derived
Ang-2 induces chemotaxis of Tie2+ macrophages and mono-
cytes. THP-1 Tie2+ monocytes but not Tie2− migrate towards
Ang-2 in the Boyden chamber model [76]. U937 monocytes
exposed to Kaposi’s sarcoma EC conditioned media migrate
towards the conditioned medium compartment. This
Cancer Metastasis Rev
migration is abolished with anti-Ang-2 antibody or with Ang-
2 shRNA in ECs [56]. Hence, Ang-2 expression and release
by EC are tightly regulated and promote TEM migration
in vitro.
In vivo, Ang-2 induces Tie2+ TAM and TEM infiltration
by stimulating the expression of their Ang-2 receptor Tie2.
Indeed, Ang-2 induces macrophage and TEM infiltration that
is correlated with metastasis in murine MDA-MB-231-
induced breast cancer, in pancreatic cancers, in lung cancer,
in Kaposi’s sarcoma, in glioblastomas (GBMs), and in glio-
mas [56–58, 74, 77]. Indeed, specific EC Ang-2 overexpres-
sion increases macrophage and TEM infiltration in murine
GBM and LLc lung tumor models [57, 58]. Ang-2 inhibition
diminishes TAM and/or TEM infiltration in Kaposi’s sarcoma
and breast cancer murine models [56, 59]. Nonetheless, in
MMTV-PyMT breast cancer and Rip1-Tag2 pancreatic can-
cer, Ang-2 inhibition does not modify macrophage or TEM
infiltration but rather inhibits their perivascular localization
[78]. Ang-2 blockade induces SDF1α overexpression in the
MMTV-PyMT model, which can counterbalance the effects
of Ang-2 blockade on TAM and TEM infiltration. Ang-2
induces EC ICAM1 and VCAM1 expression that hence in-
creases monocyte and TAM adhesion on EC [77]. Moreover,
Ang-2 increases vessel permeability, angiogenesis, and CCL2
expression in ECs that also leads to C-C chemokine receptor
type 2 (CCR2)+ monocyte and TAM infiltration [77, 79].
Hence, in tumors, Ang-2 is an important EC-secreted protein
that is involved in macrophage and monocyte Tie2+
Fig. 1 Effects of blood vessels onmonocyte/macrophage recruitment and
polarization. a Effects of ECs and pericytes on monocyte/macrophage
recruitment. ECs secrete high dose of Ang-2 which induces TEM recruit-
ment in tumor [56–59]. Furthermore, Ang-2 promotes angiogenic pheno-
type in TEMs and in Tie2-expressing macrophages [58]. Homophilic
interaction between Clever-1 in ECs and TAMs induces TAM infiltration
[60]. ECs secrete CX3CL1 which induces CX3CR1-expressing mono-
cyte (non-classical monocyte) chemotaxis toward ECs [21, 61].
CX3CL1/CX3CR1 interaction induces non-classical monocyte recruit-
ment via VEGF-A-dependent CX3CL1 shedding [21, 62, 63]. IL-33
secreted by pericytes promotes TAM recruitment via the IL-33 receptor
ST2 activation [64]. b Effects of ECs and pericytes on TAM survival and
polarization. CSF1 promotes TAM survival in the TME via CSF1R acti-
vation [65]. ECs are high IL-6 producer. EC-derived IL-6 induces TAM
M2 polarization [12]. Osteopontin-induced EndMT promotes M2 TAMs
polarization via HSP90⍺ secretion [66]. Radiotherapy-induced EndMT
induces CXCR4 expression in ECs, which promotes SDF1α-expressing
TAM M2 polarization [67]. IL-33 secreted by pericytes promotes M2
polarization in a ST2-dependent manner [68]. This figure was created
with BioRender.com
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infiltration and perivascular localization. Moreover, Ang-2-
induced EC CCL2 overexpression induces CCR2+ IM
recruitment.
In line with the fact that Ang-2 induces TAM and TEM
infiltration, Ang-2 expression is correlated with microvascular
density and associated with poor prognosis in several cancers
[71]. Furthermore, Ang-2 is overexpressed in tumor tissues
compared to normal tissues [71]. Ang-2 expression is in-
creased by anti-VEGF therapies in tumor but not in normal
tissues [76, 80–82]. This Ang-2 overexpression leads to ther-
apy failure by increasing TEM and TAM infiltration. This
TAM recruitment induced by anti-VEGF therapy is blocked
by the addition of Ang-2 antibody or soluble Tie2 [76]. This
bitherapy has been tested in phase I in human cancer patients
and showed acceptable safety and encouraging antitumor ac-
tivity [83]. To summarize, Ang-2 is involved in tumor resis-
tance against VEGF therapy and anti-Ang-2/VEGF combina-
tion shows encouraging results in pre-clinical and clinical
studies.
2.1.2 Pericytes and perivascular cancer-associated fibroblasts
in TAM recruitment
Pericytes and perivascular cancer-associated fibroblasts
(CAFs) are involved in TAM recruitment and their
perivascular localization. Platelet-derived growth factor
(PDGF)-BB secretion by cancer cells induces IL-33 expres-
sion and secretion by pericytes and CAFs via a PDGF receptor
β (PDGFRβ)–dependent mechanism. IL-33 further stimu-
lates macrophage migration in vitro and TAM infiltration
in vivo via the IL-33 receptor ST2–dependent mechanism
[64]. Indeed, pericytes exposed to PDGF-BB in vitro or
in vivo in lung tumor model with LLc overexpressing
PDGF-BB overexpress IL-33 and this overexpression is
abolished by anti-PDGFRβ antibodies. IL33-induced RAW
cell migration is abolished by ST2 RAW siRNA. In vivo,
TAM infiltration is increased in tumors overexpressing
PDGF-BB. This increase is abolished in mice IL-33−/−,
ST2−/− or with ST2 soluble factors. These IL-33 recruited
TAMs are also involved in tumor growth and in cancer cell
stemness via prostaglandin 2 secretion [84]. Milk fat globule-
epidermal growth factor 8 (MFG-E8), expressed mostly by
pericytes in melanoma tumors, is also involved in TAM infil-
tration by an unknownmechanismwhich would be interesting
to clarify [85]. Consistently, high MFG-E8 expression is as-
sociated with high TAM infiltration in bladder cancer [86]. As
said above, TAMs are also classified according to their tumor
localization in which there are migratory TAMs and
perivascular TAMs [4, 17]. In fact, there is a unidirectional
mechanism by which a newly recruited monocyte will differ-
entiate in migratory TAMs which then will be recruited to
blood vessels and hence become perivascular [17]. Indeed,
in the mammary PyMT model, newly tumor-infiltrated blood
CCR2+ monocytes are recruited by cancer cell– and stromal
cell–derived CCL2. Then, monocytes differentiate into migra-
tory TAMs and C-X-C chemokine receptor type 4 (CXCR4)
expression by TAMs is then promoted by tumor-derived
transforming growth factor-β (TGF-β). These migratory
TAMs are then recruited near to the blood vessel by
SDF1α-derived perivascular CAFs [17]. In summary,
perivascular cells are involved in TAM recruitment via IL-
33 secretion and in TAM perivascular localization via
SDF1α secretion.
2.1.3 Monocyte/TAM recruitment via direct interactions
with ECs
Whereas most endothelial-leukocyte adhesion molecules are
shared between all leukocyte types [46], monocytes and
TAMs are also specifically recruited by tumor ECs [46].
Clever-1/stabilin-1+ is a scavenger receptor and an adhesion
molecule regulating macrophage and T regulator lymphocyte
transendothelial migration as well as tumor infiltration [60,
87]. Indeed, Clever-1 overexpressing ECs are involved in
Clever-1+ monocyte/macrophage and Treg recruitment [60].
Indeed, Clever-1 deletion in mice or specifically in macro-
phages or in ECs leads to a diminished TAM recruitment,
without affecting lymphocyte CD4+ or CD8+ recruitment
[60]. Apoptosis signal-regulating kinase 1 (ASK1), a factor
involved in the regulation of EC activation, is involved in
TAM recruitment in tumor, without affecting lymphocyte
CD3+ recruitment [88, 89]. In non-inflammatory conditions,
ASK1 is consistently degraded via suppressor of cytokine
signaling 1 (SOCS1) by the proteasome and pushes ECs in
an inactivated state. In inflammatory condition, ASK1 is sta-
bilized and stimulates EC activation via JNK/p38MAPK ac-
tivation [89]. EC ASK1 expression induces macrophage infil-
tration into tumors without affecting lymphocyte recruitment
[88]. TAM infiltration in tumors is decreased in ASK1 KO
mice or with ASK1 inhibition specifically in EC (via SOCS1
overexpression specifically in EC) or with ASK1 inhibitor.
This TAM infiltration prevention by ASK1 inhibition leads
to a decrease in tumor growth and in metastasis and to an
increased survival in mice [88]. Nonetheless, the mechanism
by which ASK1 leads to specific TAM infiltration remains
unclear and it would be interesting to be investigated. That
could be either by chemotactic factor over-secretion specifi-
cally inducing TAM infiltration (e.g., CCL2, Ang-2) or via a
direct contact between TAMs and ECs inducing TAM trans-
migration (e.g., via Clever-1 interaction). In vitro, TAM trans-
migration is impaired across EC ASK1–specific inhibition,
but the lymphocyte transmigration has not been investigated
[88]. All these data demonstrate that homophylic interaction
between EC and macrophage Clever-1/stabilin-1 is involved
in TAM recruitment into tumor without affecting CD4+ or
CD8+ lymphocyte recruitment.
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2.1.4 CX3CL1/CX3CR1 axis in non-classical monocyte
recruitment
Chemokine (C-X3-C motif) ligand 1 (CX3CL1) expres-
sion in ECs is involved in the CX3CL1 receptor
(CX3CR1)–dependent recruitment of immune cells, such
as NK cells, CD8+ T cell, and CX3CR1 non-classical
monocytes [90]. CX3CL1 expression in EC specifically
regulates CX3CR1-expressing monocyte recruitment into
tumors without affecting IM recruitment. This process may
be also involved in TEM recruitment since around 50% of
TEMs express CX3CR1 [29]. CX3CL1 exists as mem-
brane bound and soluble forms. Soluble CX3CL1 is in-
volved in CX3CR1 monocyte chemotaxis, whereas mem-
brane bound is involved in their adhesion to ECs [61, 91].
Indeed, soluble CX3CL1 induces human peripheral blood
mononuclear cell–derived monocyte migration, more ef-
fectively than CCL5 [91]. CX3CL1+ monocytes adhere to
HEK293 overexpressing membrane bound CX3CR1 but
not to WT HEK293. The membrane-bound CX3CL1 pro-
motes human non-classical monocyte crawling and adhe-
sion on endothelium via CX3CR1 activation on non-
classical monocytes [21]. The subsequent monocyte trans-
migration is promoted by angiogenic factors such as
VEGF-A. VEGF-A involvement in non-classical mono-
cyte transmigration is due to VEGF-A-induced a
disintegrin and metalloproteinase domain–containing pro-
tein 10 (ADAM10) and ADAM17 activity stimulation [62,
63], which subsequently promotes CX3CR1 monocyte
transmigration via CX3CL1 shedding [92] and hence
non-classical monocyte transmigration. Consistently with
these results, in vitro transendothelial migration and in vivo
infiltration of non-classical monocytes into tumors are crit-
ically lower in non-angiogenic tumors, whereas they are
increased in angiogenic tumors [21]. Indeed, human non-
classical monocytes are recruited mostly in DLD1 or
HCT116 tumor expressing high level of VEGF-A, whereas
they are less recruited in SKBR1 tumor expressing low
level of VEGF-A. Furthermore, treatment of DLD1 tumors
with anti-VEGF-A antibody bevacizumab reduces the hu-
man CD16+ monocyte recruitment. Nonetheless, the
DC101 anti-VEGFR2 antibody increases Ly6Clo mono-
cyte infiltration into orthotopic murine colorectal tumors.
Furthermore, non-classical monocytes require CX3CR1 to
infiltrate tumors since Ly6Clo monocytes infiltration in
murine orthotopic colorectal tumors is abolished in
CX3CR1 KO mice [22]. These data suggest that the inter-
action between CX3CL1 (EC) and CX3CR1 (non-classical
monocyte) promotes non-classical monocyte recruitment
into tumor. This recruitment is enhanced in angiogenic
tumors and it would be interesting to investigate if this
process is involved in TEM infiltration since 50% of
TEMs express CX3CR1.
2.2 Impact of blood vessel cells on macrophage
polarization and angiogenic phenotype (related to
Fig. 1b)
2.2.1 ECs promote M2 polarization and angiogenic
phenotype
ECs are involved in macrophage survival, proliferation,
M2-polarization, and angiogenic phenotype acquisition in
malignant and non-malignant tissues [12, 54, 65]. The im-
pact of ECs on macrophage survival has been demonstrat-
ed by co-culture experiments. The macrophage survival
and expansion are mediated by direct contact between
ECs and macrophages since macrophage colony formation
is observed with direct co-cultures but not with transwell
assays. CSF1-membrane bound (EC) and CSF1 receptor
(CSF1R) (macrophage) juxtacrine interaction is involved
in macrophage survival and expansion, since a CSF1 ex-
clusive inhibitor inhibits macrophage survival and expan-
sion [65]. This survival/proliferation induced by ECs in
macrophages is likely due to mechanistic target of
rapamycin (mTOR) activation in macrophage since
mTOR inhibition with rapamycin inhibits CSF1+IL-6-in-
duced macrophage proliferation [12]. Furthermore, ECs
induce M2 polarization in vitro and in vivo, notably via
IL-6 secretion [12, 54]. Indeed, the macrophage-EC co-
cultures increase M2 marker expression such as Tie2 and
decrease M1 marker expression such as major histocom-
patibility complex II (MHCII) [65]. Furthermore, EC con-
ditioned media induce M2 polarization associated with the
enhanced expression of CD206 or Arg-1, which is reduced
by anti-IL-6 antibody [12]. This M2 polarization is en-
hanced in pre-incubated ECs with GBM cells which seems
that this EC-induced M2 polarization is amplified by the
TME. In human and murine GBM, alternatively activated
TAMs are localized proximately to ECs, which are a major
source of IL-6. Indeed, in vivo, specific inducible deletion of
IL-6 in ECs reveals that ECs are the major source of IL-6 in
murine GBM [12]. Furthermore, IL-6 expression is highly de-
tected in ECs cytoplasm of newly formed vessels in human
GBM [93]. Specific inducible deletion of IL-6 in ECs strongly
decreases M2 macrophage population and slightly increases
M1 population, decreases tumor growth, and enhances mice
survival [12]. In summary, ECs are involved in macrophage
survival and expansion via CSF1-CSF1R juxtacrine loop, and
in macrophage M2 polarization, notably via IL-6 secretion
in vivo, at least in murine GBM.
ECs induce angiogenic phenotype in macrophages as-
sociated with an increase in Tie2 or VEGF-A expression
and macrophages co-cultivated with ECs increase murine
prostate tumor growth and angiogenesis, when these mac-
rophages are co-injected with cancer cells in mice [65].
EC-derived Ang-2 is not only a chemoattractant for
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TEMs. Indeed, Ang-2 also promotes M2 polarization and
angiogenic profile in TEMs by increasing the expression of M2
markers (IL-10 and MRC1) and of angiogenesis-related gene
(cathepsin B and thymidine phosphorylase) expression [58].
Furthermore, in vivo, Ang-2 and Ang-2 + VEGF inhibitions
shift macrophage population from M2 towards M1. Anti-
Ang-2 increases M1/M2 intermediate macrophage population
in murine GBM. Anti-Ang-2 combined with an anti-VEGF
increases M1 proportion among total leukocytes in the PyMT
model and increases M1 population and decreases M2 popula-
tion among total macrophages [81, 94]. Hence, Ang-2 is in-
volved in macrophage and TEMM2 polarization and promotes
their angiogenesis phenotype.
2.2.2 Endothelial-to-mesenchymal transition (EndMT)
promotes macrophage M2 polarization
Endothelial-to-mesenchymal transition (EndMT) is de-
fined as a phenotypic change in ECs characterized by a
loss of endothelial features, markers (e.g., CD31), cellular
tight junctions, apico-basal polarity, and the acquisition of
mesenchymal features and markers such as fibroblast spe-
cific protein-1 and α-smooth muscle actin (α-SMA) [95].
EndMT is a source of up to 40% of CAFs; can be induced
by radiotherapy, TGFβ-1, or osteopontin; and has an im-
pact on tumorigenesis, metastatic extravasation, and ther-
apy resistance [67, 95–98]. Radiotherapy-induced EndMT
is mediated via p53 activation in ECs, whereas it is me-
diated via transcription factor 12 (TCF12) in osteopontin-
induced EndMT since p53 siRNA and TCF12 shRNA
inhibit radiotherapy-induced EndMT and osteopontin-
induced EndMT, respectively. Furthermore, ECs undergo-
ing EndMT with osteopontin or radiotherapy induce M2
polarization and inhibit M1 polarization [66, 67]. This is
mediated via heat shock protein 90 α (HSP90α) secretion
by osteopontin-induced EndMT, whereas it is mediated
via CXCR4/SDF1α signaling in radiotherapy-induced
EndMT [66, 67]. In vitro, osteopontin-induced EndMT
conditioned media induce THP-1-derived macrophage
M2 po l a r i z a t i o n wh i c h i s b l o c k e d b y a n t i -
HSP90α antibody. On the other hand, bone marrow–
derived macrophages (BMDMs) co-cultivated with irradi-
ated tumor ECs display an increased CD206+ M2 macro-
phage proportion (in total F4/80+ macrophage population)
compared with non-irradiated ECs. This effect is
abolished in BMDMs co-cultivated with tumor ECs from
EC-p53 KO mice. Furthermore, in vivo, subcutaneous co-
injection of osteopontin-induced EndMT cells with
Panc02 pancreatic cancer cells drastically enhances M2
macrophage population and tumor growth (compared with
Panc02 injected alone or injected with ECs). These chang-
es are strongly reduced with intravenously injected anti-
HSP90α antibody [66]. Irradiation induces CXCR4
expression in ECs both in vitro and in vivo. This effect
is abolished with p53 siRNA and in EC-p53 KO mice.
The irradiation-induced CXCR4 expression induces mac-
rophage SDF1α + recruitment and M2 polarization in vivo
since this is inhibited with CXCR4 antagonist [67].
Consistently with these results, in human PDAC, there is
a correlation between EndMT numbers and M2 macro-
phage infiltration. Furthermore, M2 macrophages are lo-
cated close to EndMT cells [66]. All together, these data
ev idence tha t ECs undergoing os teopont in- or
radiotherapy-induced EndMT induce macrophage M2 po-
larization in murine tumors via HSP90α secretion and
CXCR4/SDF1α signaling, respectively.
2.2.3 Pericytes and perivascular mesenchymal stem cells
(MSCs) induce macrophage M2 polarization
Perivascular cells regulate macrophage polarization in mel-
anoma and pancreatic cancers. In melanoma, pericytes and
MSCs influence macrophage polarization notably via
MFG-E8 secretion [99]. MFG-E8, also called lactadherin,
i s a secre ted in tegr in -b ind ing pro te in which i s
overexpressed in several tumor types compared to normal
tissues [100]. MFG-E8 promotes cancer progression, cancer
chemoresistance, and tumor angiogenesis and is associated
with poor prognosis in human melanoma. Pericytes and
perivascular MSCs are the major sources of MFG-E8 secre-
tion in melanoma tumors [85, 99]. MFG-E8 is involved in
macrophage M2 reprograming since macrophage incuba-
tion with MFG-E8 induces IL-10, TGF-β, and VEGF-A
secretion, and increases the proportion of CD206+ macro-
phages [101]. MFG-E8 released by apoptotic ECs or MSCs
is also involved in M2 polarization [85, 101]. Indeed,
in vitro, RAW macrophages co-cultivated with MSCs dis-
play higher M2 marker expression, which is not observed in
macrophages co-cultivated with MSC MFG-E8 KO.
Nonetheless, the way by which MFG-E8 induces M2 polar-
ization still needs to be investigated. In vivo, MFG-E8 en-
hances tumor angiogenesis and tumor growth. Furthermore,
higher vascularization is observed in MFG-E8 WT mice
compared to MFG-E8 KO [99]. This angiogenesis enhance-
ment is likely due to MFG-E8-induced macrophage M2 po-
larization. In pancreatic cancers, pericytes and CAFs are the
main cells responsible for IL-33 secretion in the TME [68].
IL-33 causes M2 polarization and matrix metalloprotease-9
(MMP-9) expression in TAMs, which are mediated by the
IL-33 receptor ST2 activation. MMP-9 and M2 polarization
induce cancer cell intravasation and metastasis in vivo [68].
Furthermore, IL-33 induces TAM prostaglandin-2 secretion
which enhances cancer stemness and tumor growth [84]. To
conclude, perivascular cells induce TAMs M2 and pro-
angiogenic phenotype via MFG-E8 and IL-33 secretion,
which impacts tumor growth.
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3 Effects of TAMs and monocytes on tumor
blood vessels
3.1 Angiogenesis and TAMs (related to Fig. 2)
Angiogenesis refers to the formation of new blood vessels
from pre-existing ones [124]. Tumor blood vessels are critical
in regulating tumor growth via oxygen supply and in
supporting metastasis via cancer cell dissemination.
Microvessel density corresponds to the small blood vessel
density in a tumor and hence is the reflection and a way to
assess tumor angiogenesis [125]. It is well described that
microvessel density correlates with angiogenic factors, metas-
tasis risk, and prognosis in a huge panel of solid tumors [125,
126]. TAMs are important regulators of tumor angiogenesis
[5]. Correlation between TAMs, microvessel density, and
poor prognosis is observed in a lot of solid tumors. TAMs
are involved in tumor blood vessel development and in the
angiogenic switch [32, 127]. Indeed, in the early stage of
tumor development, the vessel network development is ob-
served several weeks earlier in CSF1-overexpressing mice
than that in WT mice. TAMs promote tumor angiogenesis
Fig. 2 Mechanisms of tumor angiogenesis and lymphangiogenesis
promotion by TAMs and TEMs. Effects of TAMs and TEMs on
angiogenesis (a, b, c) and lymphangiogenesis (d). a TAMs and TEMs
promote tumor angiogenesis via secreted factors [5]. EC-derived Ang-2
enhances the pro-angiogenic phenotype of TEMs [58, 102]. b TAMs and
TEMs promote tumor angiogenesis via the secretion of protease. TAMs
secrete MMP-9, cathepsin B, and cathepsin S, whereas TEMs secrete
high level of MMP-9 [58, 103–105]. MMP-9 increases VEGF-A bio-
availability via ECM degradation [106, 107]. Cathepsin S is involved in
the degradation of anti-angiogenic proteins and in the formation of pro-
angiogenic peptides via ECM degradation [108]. The promotion of an-
giogenesis by cathepsin B occurs via the induction of VEGF expression
by cancer cells [109, 110]. All together, these proteases lead to an increase
and a decrease of pro-angiogenic factor and anti-angiogenic factor in the
TME, respectively, which promote tumor angiogenesis. c Upper panel:
Vascular mimicry structures are perfused non-endothelial channels. They
are formed by cancer cells in several cancer types, and promote tumor
growth, metastasis, and angiogenesis [111, 112]. TAMs promote, at least
in vitro, the formation of vascular mimicry channels by cancer cells [113,
114]. Lower panel: TAMs can directly form vascular mimicry structures
in tumors [115] . d Upper pane l : TAMs promote tumor
lymphangiogenesis via the secretion of VEGF-C, VEGF-D, and LCN2
[116–118]. Furthermore, podoplanin-expressing macrophages (PoEMs)
are able to interact with tumor LECs and are strongly involved in the
promotion of tumor lymphangiogenesis [119–121]. This interaction is
dependent on GAL8 (LECs), podoplanin, and β1 and β4 integrins
(PoEMs) [119, 121]. The secretion of Semaphorin 7A by cancer cells
promote the expression of podoplanin by TAMs [120]. Lower panel:
TEMs and a subset of TAMs (called M-LECP) are able to integrate into
pre-existing lymphatics, which promotes tumor lymphangiogenesis [122,
123]. This figure was created with BioRender.com
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by pro-angiogenic factor secretion, protease secretion, and
transdifferentiating themselves into vessel-like structures in a
process called “vascular mimicry.”
3.1.1 Pro-angiogenic factor secretion
Once in the tumor, TAMs secrete pro-angiogenic factors such
as VEGF-A, TGF-β, fibroblast growth factor-2 (FGF-2),
CCL18, semaphorin 4D (Sema4D), adrenomedullin (ADM),
and placental growth factor (PlGF) [128–133]. Macrophage
pro-angiogenic phenotype is regulated by hypoxia and lactate.
Indeed, in vitro, conditioned media from macrophages ex-
posed to lactate or hypoxia have higher angiogenic capacity
than conditioned media from macrophages exposed to
normoxia, as shown in rat corneal angiogenesis assays
[134]. Hypoxia and lactate induce VEGF-A expression in
macrophages via hypoxia-inducible factor-1α (HIF-1α), since
this is abolished in macrophage from HIF-1α KO mice [135,
136]. It is strongly suggested in [136] that tumor-derived lac-
tate induces TAM M2 phenotype and promotes their angio-
genic phenotype. Very recently, it was shown that the expres-
sion of the lactate transporter MCT1 by macrophages is
strongly involved in lactate uptake and oxidation by macro-
phages and in lactate-induced macrophage M2 polarization
and VEGF secretion [137]. Furthermore, in vitro, HIF-1α
and HIF-2α stability in macrophage is regulated by PI3K/
Akt signaling, since HIF-1α, HIF-2α, and VEGF induction
by hypoxia is strongly inhibited with PI3K inhibitors or AKT
siRNA [138]. In vivo, TAM angiogenic phenotype and
microvessel density are reduced in tumors exposed to PI3K
inhibitor or in p110γ−/− (a subunit of PI3K) mice. In tumors,
TAMs are major VEGF producers and are located mostly in
avascular and hypoxic areas [70, 136, 139]. In breast cancer,
VEGF-A and TGF-β expression and secretion in TAMs are
also regulated by cancer cells, notably via macrophage Fra-1
activation [132]. In vitro, Fra-1, VEGF-A, and TGF-β expres-
sion in macrophages from Balb/c mouse peritoneum co-
cultivated with 4T1 breast cancer cells is enhanced, whereas
Fra-1 siRNA diminish the enhanced VEGF-A and TGF-β
expression. In vivo, co-injection of 4T1 and RAW macro-
phages subjected to Fra-1 knockdown in Balb/c mice induces
tumor with less VEGF-A and TGF-β expression and with
lower microvessel density than in 4T1 and RAW WT co-
injected tumors [132]. FGF-2 expression and secretion in
TAMs are regulated by the long non-coding RNA
MALAT1. In vitro, MALAT1 knockdown in TAMs inhibits
FGF-2 expression and secretion. MALAT1 siRNA dimin-
ishes the vascular structure formation induced by TAMs con-
ditioned media in HUVECs and is reversed in TAMs overex-
pressing FGF-2 [133]. Sema4D expression and CCL18 ex-
pression in TAMs are correlated with microvascular density
and these two proteins are mainly produced by TAMs [129].
In vitro, CCL18 induces EC tube formation via the CCL18
receptor PITPNM3 activation since this CCL18-induced tube
formation is decreased in si-PITPNM3 HUVECs.
Microvascular density in tumor xenografts treated with
CCL18 is higher than that in the control. High angiogenesis
inhibition is observed in Sema4D KO mice. The injection of
WT TAMs in sema4D mice enhances angiogenesis to the
same extent as that in WT mice, whereas the injection of
sema4D KO TAMs does not [128]. In vitro, ADM secretion
by macrophages is enhanced by melanoma cancer cells.
TAMs promote angiogenesis via ADM secretion in ECs since
these TAM conditioned media–induced angiogenesis is
abolished by anti ADM. In vivo, colocalization between
CD68+ RAW macrophages and ADM indicates that TAMs
are a source of ADM in this melanoma murine model [131].
3.1.2 Protease secretion
TAMs also promote angiogenesis via the secretion of prote-
ases such as cathepsins (S and B) and MMPs such as MMP-9.
In vitro, cathepsin S and B secretion by macrophages is stim-
ulated by the combination of M2 polarization cytokines such
as IL-4, IL-10, and IL-6. This occurs in an inositol-requiring
enzyme 1α (IRE1α)–dependent manner since this secretion
stimulation is abolished with both IRE1α inhibitor and siRNA
[140]. In vivo, TAMs promote angiogenesis in PDAC murine
tumor model via cathepsin B and S secretion. Indeed, Rip1-
Tag2 tumors inoculated with BMDMs from cathepsin B and S
KOmice have a lower average vessel density than Rip1-Tag2
tumors inoculated with BMDMs from WT mice [103].
Furthermore, cathepsin S promotes angiogenesis in pancreatic
Rip1-Tag2 tumors via matrix protease activity leading to an
increase in pro-angiogenic factor release and in anti-
angiogenic factor degradation [108]. Cathepsin B angiogene-
sis regulation is not fully understood but cathepsin B down-
regulation in multiple models leads to angiogenesis inhibition.
VEGF secretion by cancer cells and in tumor is regulated by
cathepsin via an unknown mechanism and could explain the
positive impact of cathepsin B on tumor angiogenesis [103,
140–144]. Indeed, cathepsin B inhibition or overexpression in
GBM cell lines respectively decreases or increases VEGF
secretion by these cells. Furthermore, VEGF protein level is
higher in breast tumor from mouse PyMT overexpressing ca-
thepsin B than that in tumor from PyMTWT mice [109, 110,
141]. In Rip1-Tag2 pancreatic tumors, MMP-9 is involved in
the angiogenic switch by the VEGF-A bioavailability en-
hancement [106, 107]. In vitro, M2 macrophages secrete high
levels of MMP-9 and low levels of tissue inhibitor of metal-
loproteinase (TIMP)1, a MMP inhibitor, whereas M1 macro-
phages secrete both MMP-9 and TIMP1 [145]. Hence, cancer
cells by skewing TAMs toward M2 phenotype promotes
MMP-9 activity. Accordingly, M2 macrophages favor angio-
genesis in vivo in a MMP-9-dependent manner since this abil-
ity is decreased in MMP-9 KO macrophages [145]. MMP-9
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expression in macrophages is regulated by the M2 polariza-
tion marker cyclooxygenase 2 which is activated notably by
MMP-1/3 and IL-6 [146, 147]. In vivo, tumor angiogenesis is
strongly inhibited in MMP-9 KO mice or by chemical com-
pounds inhibiting MMP-9 [104, 106]. In tumors, MMP-9 is
strongly expressed in immune cells [148], mostly by neutro-
phils [145]. Although neutrophils constitute the major source,
TAMs are also high MMP-9 producers, as shown in human
colon cancer and in murine cervical cancer [104, 149]. MMP-
9 expression and activity in tumors and in TAMs increase
during tumor progression of the Rip1-Tag2 cancer model
[104].
3.1.3 Vascular mimicry
Vascular mimicry, also called vasculogenic mimicry, refers to
vascular channels formed by non-endothelial cells (mostly
cancer cells). These structures were firstly described by
Maniotis et al., in 1999 [150]. They showed that highly inva-
sive melanoma cells, which notably are expressing high level
of tie1, were able to form vascular perfused channels both
in vitro and in vivo. Nowadays, it is known that vascular
mimicry networks are also observed in numerous cancer types
[111, 112, 151]. These vascular mimicry channels are per-
fused and connected to the general circulation. They are
known to increase tumor growth and to be associated with
poor prognosis and metastasis in patients [111, 112].
In vitro, M2 macrophages induce vascular mimicry in gli-
oma and GBM cells [113, 114]. The macrophage-induced
vascular mimicry in gliomas cells is dependent on IL-6 and
COX2 induction in gliomas and GBM cells, respectively.
Indeed, IL-6 expression inhibition in glioma cells and COX2
inhibition in GBM cells abolish the impact of macrophages on
vascular mimicry formation by these cells. This is consistent
with the fact that, in GBM patients, vascular mimicry positive
areas display high TAMs infiltration. Furthermore, in glioma
patients, vascular mimicry density is correlated with the quan-
tity of M2 macrophages. In uveal melanoma, there are more
macrophages in tumors having vascular mimicry than in those
without vascular mimicry [152]. The correlation between
macrophages and vascular mimicry appearance in tumors
may be due to hypoxia since hypoxia promotes the formation
of vascular mimicry as well as the infiltration of macrophages
[69, 70, 153]. It would hence be interesting to investigate if
TAMs induce vascular mimicry formation by cancer cells
in vivo.
TAMs can also form vascular mimicry structures in vitro
and in vivo in melanoma tumor model, in multiple myeloma,
in human anaplastic thyroid carcinoma, in human meningio-
ma, and benign melanoma tumor [115, 154, 155]. In vitro,
exposure of multiple myeloma macrophages to VEGF and
FGF-2 induces a capillary-like network associated with in-
creased EC marker expression (factor VIII–related antigen,
VE-cadherin, and VEGFR2) [154]. In the murine melanoma
tumor model, these channels are functional, perfused, and
connected to the vasculature since dextran is detected in these
structures upon its injection in the tail vein [115]. Hypoxia is a
key factor involved in vascular mimicry formation since less
vascular mimicry channels are formed with HIF-1α KO mac-
rophages [115]. Consistently with these results, in human an-
aplastic thyroid carcinoma, cancer cells that are closed to these
macrophage channels are not necrotic or hypoxic, even at long
distance from blood vessels [155]. This indicates that these
channels are perfused or at least lead to tumor cell oxygena-
tion. Additionally, vascular mimicry is observed in human
malignant meningioma and benign melanoma tumors [115].
The functional significance of these TAM-derived vascular
mimicry structures for tumor growth, angiogenesis, metastasis
as well as for prognosis is thus worth investigating.
3.1.4 Communication with pericytes
The effects of TAMs on blood vessel angiogenesis rely on
communication not only with ECs but also with pericytes.
This communication between macrophages and pericytes oc-
curs notably via Notch signaling and PDGFB-PDGFRβ-
induced pericyte migration and periostin expression [156,
157]. In vitro, HUVEC cells co-cultivated with macrophages
or pericytes enhance the formation of microvessels.
Furthermore, the triple co-culture of macrophages, pericytes,
and ECs is synergic in promoting angiogenesis. Notch signal-
ing is involved in this process since Notch inhibition in each
cell type inhibits angiogenesis [157]. In vitro, the secretion of
PDGF-BB by macrophages induces pericyte PDGFRβ+ mi-
gration and secretion of VEGF-A and pro-angiogenic extra-
cellular matrix component (ECM) periostin by pericytes
which enhance angiogenesis [156]. The expression and secre-
tion of PDGF-BB by macrophages are promoted by IL-4 and
IL-13 but not by IL-10 [158]. The induction of PDGF-BB
expression by IL-4 is mediated at least by PI3Kγ since this
induction is diminished in macrophages from p110γKOmice
[159]. Accordingly, PDGF-BB expression and secretion are
higher in M2 macrophages compared to M1 macrophages
[158, 160]. PDGF-BB expression and secretion in macro-
phages are also stimulated by cancer cells. In vitro, macro-
phages exposed to U87 GBM cancer cells show higher
PDGF-BB expression. This induction occurs via cat eye syn-
drome critical region protein 1 (CECR1) induction since it is
abolished in siRNA CECR1-treated macrophages [156].
Furthermore, the stimulation of TAMs with CECR1 induces
PDGF-BB expression in TAMs. Consistently with this,
CECR1 expression in GBM is highly produced by TAMs
and is correlated with human GBM microvascular density
[156, 161]. In vivo, in the early steps of murine brain tumors,
macrophages are involved in pericyte-endothelial interaction
and thereby in tumor angiogenesis. Indeed, neural glial
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antigen 2 (NG2) KO specifically in macrophages strongly
decreases macrophage recruitment during the beginning of
murine brain tumors. Then, macrophage recruitment returns
to the same level as in WT tumors in the later stages of tumor
growth [162]. Interestingly, macrophage recruitment is corre-
lated with the level of tumor blood vessel covered with
pericyte and tumor angiogenesis, indicating that macrophages
are most likely involved in these processes. Indeed, 10 days
after the development of NG2 macrophage KO tumor, mac-
rophage infiltration is reduced by 90% compared to WT tu-
mors. This decrease in macrophage infiltration is associated
with a lower pericyte coverage of tumor blood vessels. After
16-day tumor development, macrophage infiltration and
pericyte coverage of tumor blood vessel are comparable in
NG2 macrophages KO mice and in WT mice. In conclusion,
TAM communication with pericytes promotes angiogenesis
in vitro, via Notch signaling and secretion of PDGF-BBwhich
induces pericyte recruitment. In the early steps of murine brain
tumors, TAMs promote angiogenesis and the pericyte cover-
age of tumor blood vessels. Hence, it would then be interest-
ing to investigate the impact of TAM-derived PDGF-BB and
Notch signaling involvement in the regulation of tumor angio-
genesis and pericyte recruitment in the early steps of other
cancer types.
3.2 TAMs promote tumor lymphangiogenesis (related
to Fig. 2)
Tumor lymphat ic vesse ls are formed via tumor
lymphangiogenesis process and are involved in the spread of
cancer cells. In tumors, VEGF-C and VEGF-D are the main
factors involved in tumor lymphangiogenesis, via VEGFR3
activation in LECs. In murine tumor models, overexpression
of VEGF-C/D increases tumor lymphangiogenesis.
Accordingly, VEGF-C/D inhibition or VEGFR3 inhibition
decreases lymph node metastasis [163]. In the TME, TAMs
are major VEGF-C and VEGF-D producers [5, 116, 117].
There exists a correlation between lymphatic vessel density
and VEGF-C/D production by TAMs. Furthermore, there is a
correlation between TAM density, lymphatic vessel density,
and lymph node metastasis in several cancers (reviewed in
[39]). Recently, TAM-derived lipocalin 2 (LCN2) was ob-
served to induce lymphangiogenesis [118, 164]. In vitro,
TAM-derived LCN2 induces LEC proliferation, which is
abolished in TAMs transfected with LCN2 siRNA. LCN2
induces lymphangiogenesis via VEGF-C expression induc-
tion in LECs, which induces VEGFR3 activation in LECs.
In vivo, LCN2 is involved in tumor lymphangiogenesis and
its associated metastases since there are less lung metastases
and lower lymphatic vessel density in PyMT LCN2 KO mice
than those in WTmice. Consistently with these results, LCN2
expression is correlated with lymph node metastasis in human
breast and colorectal cancers [165, 166].
O the r mechan i sms by which TAMs promote
lymphangiogenesis are by their abilities to become
perilymphatic and to integrate into pre-existing lymphatics
[39, 122]. These mechanisms occur in a subset of TAMs,
called myeloid-lymphatic endothelial cell progenitors (M-
LECP) [167]. These cells co-express macrophage markers
such as CD68 (human) or CD11b (mouse) and lymphatic
markers such as podoplanin and LYVE 1. These TAMs colo-
calize around lymphatic structures and compose macrophage-
derived lymphatic structures which thereby promote
lymphangiogenesis [39, 119–121]. Indeed, TAMs can
transdifferentiate into LEC progenitors and acquire LEC
markers such as LYVE 1 and podoplanin in murine and hu-
man tumors [39, 167, 168]. The adhesion between TAMs and
LECs depends on podoplanin expression in TAMs and
galectin 8 (GAL8) expression in LECs [119]. Podoplanin ex-
pression in TAMs is induced by semaphorin 7A both in vitro
and in vivo during tumorigenesis and during physiological
postpartum mammary gland involution [120]. Semaphorin
7A is also involved in macrophage motility, chemotaxis to-
wards lymphatics, and TAM incorporation in lymphatics dur-
ing lymphangiogenesis in vitro [120]. Podoplanin-expressing
macrophages (PoEMs) are located near lymphatic vessels in
murine breast cancer. The perilymphatic localization of
PoEMs is mediated by interaction with GAL8-expressing
LECs [119]. Indeed, GAL8-specific deletion in LECs or
GAL8 pharmacological inhibit ion impairs PoEM
perilymphatic localization in vivo. Furthermore, this interac-
tion between PoEMs and GAL8 induces TAMs β1 integrin
clustering which is needed for TAM-LEC adhesion. Another
team showed that TAM location around lymphatic structures
is also dependent on TAMs β4 integrin interaction with lam-
inin 5 in murine triple-negative breast cancer [121]. Finally,
PoEMs secrete high amounts of MMPs (and VEGF-C and
VEGF-D) which increases VEGF-C and VEGF-D bioavail-
ability and hence promotes lymphangiogenesis [119]. In con-
clusion, TAMs favor tumor lymphangiogenesis and their sub-
sequent lymph node metastasis, either by secreted factors
(VEGF-C, VEGF-D, and LCN2) or by integration of a subset
of TAMs, called M-LECP, into lymphatic vessels.
3.3 Angiogenesis and lymphangiogenesis promotion
by Tie2-expressing monocytes (TEMs) (related to Fig.
2)
In vitro, TEMs secrete more pro-angiogenic factors such as
VEGF-A, TNFα, cyclooxygenase 2, MRC1, and Wnt5a than
Tie2− monocytes. They are a major source of MMP-9 [58,
105]. These TEMs are recruited into tumors by EC-derived
Ang-2 (see above) [56–58, 74, 77]. Furthermore, these Ang-2-
activated TEMs secrete higher levels of insulin-like growth
factor 1 (IGF1), cathepsin B, and thymidine phosphorylase
and are more pro-angiogenic in vitro [58, 102]. TEMs are also
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pro-angiogenic in vivo. For example, the co-injection of glio-
ma or ovarian cancer cells with TEMs in mice induces more
vascularized tumors compared to injection of tumor cells
alone or of tumor cells co-injected with CD11b+ myeloid cells
without TEMs [102, 123, 169]. Ang-2-induced TEM IGF1
secretion induces angiogenesis and tumor growth via an
IGF1 receptor–dependent activation of ECs [102]. Indeed,
Ang-2-treated TEMs are more pro-angiogenic in vitro and
in vivo and this increase is abolished by anti-IGF1 antibodies.
Consistently with these results, the proportion of TEMs
amongst total tissue TAMs is correlated with total tumor mi-
crovascular density in human ovarian, renal cell carcinoma,
hepatocellular carcinoma, and non-small cell lung cancer, but
not in colorectal cancer [29, 102, 170, 171]. High TEM infil-
tration or high number of circulating TEMs is correlated with
poor prognosis in ovarian cancer and in hepatocellular carci-
noma, respectively, whereas it is surprisingly correlated with
good prognosis in hilar cholangiocarcinoma [102, 172–175].
These TEMs are also found in hypoxic and tumor areas
enriched in small immature non-pericytic blood vessels
[123, 176]. Less TAM-expressing Tie2 infiltration in murine
GBM tumors is observed in HIF-1 KO mice [176].
Interestingly, in murine and human breast cancers, TEMs ex-
press lymphatic markers (e.g., LYVE 1, VEGFR-3, and
podoplanin) and lymphangiogenic factors (VEGF-C and
VEGF-D) and are associated with lymphatic structures
[123]. These isolated breast cancer TEMs induce
lymphangiogenesis both in vitro and in vivo (as shown with
corneal vascularization assays) by Tie2- and VEGFR-1-
dependent mechanism. Indeed, TEMs isolated from breast
cancer induce lymphangiogenesis. This process is slightly
inhibited by Tie2 or VEGFR inhibitors while it is abolished
by the combination of both inhibitors. Interestingly, TEMs are
involved in chemotherapy relapse and vessel reconstruction
after chemotherapy [177]. Indeed, in murine fibrosarcoma tu-
mors, chemotherapy (doxorubicin) firstly decreases vessel
density and tumor volume which is followed by a strong in-
crease in tumor growth and vessel density (tumor relapse).
These features are correlated with TEM accumulation in the
tumors. Vessel density and tumor growth promotion by doxo-
rubicin are strongly diminished in mice with Tie2 deletion
specifically in the myeloid cells. In summary, TEMs promote
angiogenesis and lymphangiogenesis in several cancer types
and are involved in chemotherapy relapse of murine fibrosar-
coma tumors [177].
3.4 TAMs promote metastasis (related to Fig. 3)
Metastasis process is defined as the dissemination of cancer
cells from a primary tumor site into a secondary site [187].
This process is responsible for up to 90% of cancer deaths
[188]. It is composed of different steps including cancer cell
migration/invasion through ECM, cancer cell intravasation,
cancer cell circulation and survival into the blood, cancer cell
extravasation, and metastasis formation. The effects of
perivascular TAMs on blood vessels are involved in cancer
cell migration/invasion, intravasation, extravasation, and met-
astatic formation. TAM deletion in 3 different ways (CD11b+
TAM deletion, CSF1R mice KO, or clodronate liposomes)
and monocyte recruitment inhibition into the lung by CCL2
blockade all inhibit metastatic spread from primary murine
PyMT mammary tumor to lungs [16, 184].
3.4.1 TAMs and tumor ECs promote cancer cell migration
toward blood vessels
Cancer cell migration toward blood vessel is enhanced by a
paracrine loop between TAMs and cancer cells, ECs and can-
cer cells, and the three cell types. Indeed, cancer cell migration
is enhanced by perivascular TAMs involving a paracrine loop
of TAMs CSF1 secretion and epidermal growth factor (EGF)
secretion by cancer cells. Indeed, the inhibition of either EGF
or CSF1 results in strong cancer cell migration diminution
[178]. The migration of cancer cells toward blood vessels is
also stimulated both in vitro and in vivowith EC-derived HGF
which promotes cancer cell migration in a c-Met receptor–
dependent manner [179]. Breast cancer cell motility towards
HUVEC conditioned medium is impaired by cancer cell c-
Met knockdown or by HUVECs HGF knockdown.
Furthermore, cancer cell migration towards blood vessel is
impaired by c-Met inhibition in vivo in breast murine cancer.
A paracrine loop between TAMs, ECs, and cancer cells is
involved in breast cancer cell migration/invasion toward
blood vessels. Indeed, macrophage conditioned media induce
ET secretion by HUVECs and ET receptor activation in can-
cer cells. These effects create cancer cell chemotaxis toward
blood vessels which is blocked by ET-1 blocking antibody
both in vitro and in vivo [180]. This paracrine loop is also
responsible for tumor cell transendothelial migration and for
metastasis.
3.4.2 TAMs promote cancer cell intravasation in areas called
tumor microenvironment of metastasis
In breast cancer, cancer cell intravasation is enhanced in areas
called tumor microenvironment of metastasis (TMEM) which
is composed of one TAM, one cancer cell overexpressing the
invasive isoform of “mammalian enabled” protein (MenaINV;
an actin regulatory protein), and one EC, all three in direct
contact [189]. Mechanistically, direct contact of macrophages
with breast cancer cells induces Notch1-dependent MenaINV
expression in breast cancer cells [190]. Then, this interaction
induces Rhoa GTPase–mediated invadopodia which helps
cancer cells to break ECM during transendothelial migration
[181]. Furthermore, VEGF-A released by Tie2high TAMs en-
hances local and transient vascular leakiness and hence cancer
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cell transendothelial migration in vitro and in vivo [182].
TAM-derived TNF-α also enhances cancer cell migration to-
ward ECs, endothelial permeability, and cancer cell
intravasation in 3D fibrosarcoma and breast cancer models
[191]. TAM-derived IL-1β enhances cancer cell adhesion
and transendothelial migration throughout blood and lymphat-
ic cells in vitro [192]. TMEM structures are observed in early
tumor lesions from breast cancer of MMTV-PyMT and
MMTV-HER2mice [193]. Furthermore, in human breast can-
cer, TMEMs are restricted to the blood vessels (not seen in
lymphatic vessels) and a high number of TMEMs are associ-
ated with increased risk of distant metastasis and correlated
with breast cancer grade [194–196]. In conclusion, TAMs, as
a crucial part of TMEMs, are involved in breast cancer cell
intravasation and thereby involved in breast cancer metastasis.
Nonetheless, since this effect of macrophages on cancer cell
intravasation is restricted to breast cancer, it would be inter-
esting to investigate if macrophages could promote cancer cell
intravasation or if TMEM structures are observed in other
cancer types.
3.4.3 TAMs promote cancer cell extravasation, cancer cell
seeding, and distant metastasis
The extravasation step is enhanced by TAMs and monocytes,
notably via blood vessel permeabilization [16, 183]. Blood
vessel permeabilization is mostly promoted by TAM and
monocyte VEGF-A secretion and monocyte-induced endo-
thelial retraction in an E-selectin-dependent manner. In a 3D
transmigration assay, cancer cell transmigration is diminished
by 5-fold in the absence of macrophages. Interestingly, the
effects of TAMs are inhibited by CCL2 blocking antibody
and totally ablated in VEGF-A KO TAMs. TAM-secreted
VEGF-A also enhances vascular permeability [16]. VEGF-
A-induced vascular permeability is mediated by tyrosine
phosphatase density-enhanced phosphatase-1 (DEP-1)–de-
pendent Src kinase activation, which then mediates VE-
cadherin uncoupling, thereby creating endothelial gaps [197,
198]. In vivo, VEGF-A-induced tumor vascular permeability
is diminished in DEP1 KOmice or with Src inhibitor. Indeed,
there is less Evans blue diffusion in healthy and tumor tissues
Fig. 3 TAMs and inflammatory monocytes (IMs) promote tumor metas-
tasis, whereas murine non-classical monocytes prevent metastasis. a
TAMs promote cancer cell migration from primary tumor site towards
blood vessel via CSF1 (TAMs) EGF (cancer cell) paracrine loop [178].
TAMs promote endothelin secretion (ET) by ECs; moreover, ET and
HGF secretion by ECs induce cancer cell chemotaxis toward blood vessel
via ET receptor and c-Met receptor activation, respectively [179, 180]. b
In breast cancer, specific area called TMEM composed of a cancer cell, a
TAM, and an EC promote cancer cell intravasation. Basically, TAMs
induce invadopodia formation in the cancer cell which is involved in
ECM breaking during EC transendothelial migration [181].
Furthermore, Tie2high TAM-derived VEGF-A promote transient and lo-
cal vascular leakage which favor cancer cell transendothelial migration
[182]. c TAMs and IMs promote cancer cell extravasation notably via
MMP-9 and VEGF-A-dependent vascular leakage [16, 183]. d TAMs
and IMs promote metastasis and distant cancer cell seeding [16, 184].
Murine non-classical monocytes prevent distant cell seeding, notably via
IL-15-induced NK cell recruitment [24, 185, 186]. This figure was creat-
ed with BioRender.com
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(Miles assay) upon its injection in the tail vein of DEP-1 KO
mice or in Src inhibitor–treated mice than that in WT mice or
untreatedmice, respectively [197, 198]. TAM-derived VEGF-
A-induced vascular leakiness is a key factor involved in dis-
tant seeding of cancer cells and metastatic spread [16]. Indeed,
VEGF-A deletion specifically in monocytes inhibits the effi-
ciency of mammary cancer cell seeding in the lung, without
affecting monocyte recruitment into the secondary site.
Furthermore, SRC KO and DEP-1 KO mice have less meta-
static spread than WT mice [198]. Vascular leakage is also
enhanced by monocyte-derived MMP-9 and via monocyte-
induced EC retraction in an E-selectin-dependent manner
[183, 199]. In 3D in vitro model, monocyte MMP-9 secretion
induces EC tight junction zonula occludens-1 (ZO-1) and
occludin disruption, thus enhancing cancer cell extravasation
[183]. Accordingly, in murine breast cancers, monocyte/
macrophages are major MMP-9 producers and have a strong
impact on cancer cell extravasation since MMP-9 expression
and cancer extravasation are strongly reduced in tumor mice
ablated of CCR2+ inflammatory monocytes. Moreover, in co-
culture experiments, monocytes promote EC permeability and
VE-cadherin dephosphorylation, which sustains cancer cell
extravasation. This is dependent on monocyte interaction with
EC E-selectin since this is not observed with monocytes lack-
ing E-selectin ligands or with ECs from E-selectin KO mice.
Cancer cell injection into mice induces lung vessel permeabil-
ity, which depends on monocytes since this is not observed in
mice depleted of monocytes. Furthermore, upon extravasa-
tion, TAMs are involved in cancer cell invasion and seeding
in the ECM. Indeed, in 3D in vitromodel, cancer cell invasion
and migration are enhanced by pre-invaded macrophages
[183]. Furthermore, in vivo, breast cancer cell pulmonary
seeding is blocked by three different methods of macrophage
depletion and by monocyte recruitment inhibition by CCL2
blockade [16, 184]. In conclusion, TAMs and monocytes are
strong factors involved in the promotion of cancer cell extrav-
asation, cancer cell seeding, and thereby distant metastasis.
3.4.4 Murine non-classical monocytes prevent lung
metastasis
Murine non-classical monocyte (CX3CR1high/Ly6Clo) differ-
entiation and survival depend on the orphan nuclear receptor
Nr4a1, and hence, Nr4a1 KO mice have drastically less non-
classical monocytes without affecting IM or macrophage pop-
ulation. Non-classical monocytes prevent lung metastasis for-
mation in the PyMT breast cancer murine model or induced
by LLc or B16-F10 cancer cells injected intravenously [24,
185, 186, 200]. Indeed, more lung metastases are observed in
non-classical monocyte–depleted Nr4a1 KO mice upon can-
cer cells injected intravenously, and this is counteracted by
Ly6Clo monocyte injection [24]. Furthermore, PyMT mice
transplanted with bone marrow from Nr4a1 KO mice show
drastically more lung metastases than mice transplanted with
WT bone marrow, without affecting primary tumor growth
[24]. Upon cancer cell injection, non-classical monocytes in-
teract with cancer cells in a CX3CR1-dependent manner, in-
filtrate the lung, engulf cancer cell material, and promote NK
cell recruitment. These processes are responsible for the inhi-
bition of lung metastases [24]. Non-classical monocyte infil-
tration into the lungs depends on Kindlin-3 since specific
Kindlin-3 deletion in non-classical monocytes diminished
their lung infiltration after cancer cell injection. This diminu-
tion is associated with an increase in lung metastases [200].
The interactions between cancer cells and non-classical mono-
cytes and subsequent cancer cell material engulfment by non-
classical monocytes depend on CX3CR1 expression in non-
classical monocytes since these processes are decreased in
CX3CR1 KO mice [24]. The NK cell recruitment is induced
by non-classical monocytes via IL-15 secretion. Indeed,
B16F-10 primary melanoma tumors induce NK cell recruit-
ment into the lungs which is abolished with non-classical
monocyte depletion or IL-15 inhibition [186]. Non-classical
monocytes are high IL-15 producers, and this secretion is
enhanced by primary tumors [186]. Moreover, non-classical
monocytes enhance NK cell activation, notably by increasing
their stimulatory receptor expression and by diminishing their
inhibitory receptor expression [185]. Non-classical monocytes
prevent lung metastases also via targeting exosomal content
from primary tumors [201, 202]. Non-classical monocyte in-
filtration in lungs is enhanced by BAG6-presenting exosomes
and by non-metastatic A375 melanoma cell line exosomes
[201, 202].
In conclusion, several murine studies showed that murine
non-classical monocytes are involved in the prevention of
metastasis. Since some differences are observed between hu-
man and mouse monocytes [203, 204], it would be very inter-
esting to confirm/correlate the results with studies performed
with human monocytes.
3.4.5 TAMs promote tumor vessel abnormalization
Tumor blood vessels are abnormal, which means that they
have higher permeability, less pericytes, and poor architectur-
al network, functionality, and perfusion enhancing tumor hyp-
oxia and acidosis. Furthermore, the decrease in blood perfu-
sion observed in abnormal tumor vessels is responsible for the
decrease in the delivery of chemotherapeutic drugs within the
tumor. Tumor vessel “abnormalization” is the process by
which blood vessels become abnormal. TAM promotion of
vessel “abnormalization” is involved in metastasis notably by
promoting cancer cell intravasation and extravasation. M2
TAMs and VEGF and PlGF secretion by TAMs are involved
in the tumor blood vessel abnormalization. This
abnormalization is characterized by a decrease in pericyte-
covered vessels and vessel perfusion, associated with an
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increase in EC gaps and tumor hypoxia [130, 205]. The dele-
tion of VEGF specifically in myeloid cells (i.e., TAMs and
neutrophils) decreases tumor angiogenesis and promotes vas-
cular normalization characterized by an increase in pericyte
coverage associated with a decrease in vessel permeability.
Furthermore, histidin-rich glycoprotein (HRG) drastically re-
duces hepatocellular carcinoma (HCC) metastasis via the in-
hibition of M2 TAM polarization and PlGF expression in
TAMs. HRG has no effect on TAM-depleted tumors or on
tumors with PlGF KO TAMs. Tumor blood vessel
abnormalization andmetastasis are markedly inhibited inmice
with PlGF KO TAMs [130]. Interestingly, the blood vessel
normalization is proposed as an emerging concept in
antiangiogenic therapy since 2005 [206]. In conclusion,
TAMs are strongly involved in angiogenesis induction and
promotion. Blood vessels whose creation is induced by
TAMs are abnormal, notably because of TAM-derived
VEGF and PlGF which decrease the coverage of tumor blood
vessel with pericytes, and thus promoting tumor vessel per-
meability and tumor metastasis.
Interestingly, the pro-metastatic activity of TAMs in hyp-
oxia areas is regulated by metabolism. Indeed, the glycolysis
and glucose uptake by TAMs are regulated by DNA damage
responses 1 (REDD1). REDD1 deletion specifically in TAMs
enhances the glucose uptake as well as glycolysis in TAMs.
This effect induces glucose competition with ECs leading to
vessel normalization and metastasis inhibition [207]. Indeed,
REDD1 deletion in TAMs increases glycolytic metabolism in
TAMs in vitro, inhibits metastasis in multiple mouse tumor
models, and induces vessel normalization characterized by an
increase in tumor blood vessel pericyte coverage and tumor
perfusion. These effects of REDD1 deletion depend on the
increase in glycolytic metabolism in TAMs since they are
abolished when the increase in TAM glycolytic metabolism
is abolished with the glycolytic activator PFKB3 deletion
[207]. In conclusion, glucose competition between tumor
ECs and TAMs regulates blood vessel features. High glucose
consumption by TAMs reduces glucose availability to ECs
and allows the formation of a mature and poorly metastatic
vascular network. On the other hand, low glucose consump-
tion by TAMs allows high glucose uptake by ECs which
allows the formation of immature, abnormal, and pro-
metastatic leaky vessels.
4 Discussion
There are strong reciprocal interactions between tumor
monocytes/macrophages and tumor blood/lymphatic vessels.
TAMs and TEMs are involved in angiogenesis, in
lymphangiogenesis, and in multiple metastasis steps, whereas
blood vessels are involved in the recruitment of monocytes/
macrophages/TEMs into tumors and in macrophage
polarization into M2 pro-tumoral phenotype. In the last few
years, many discoveries have been made about the effects of
blood vessels on the polarization of macrophages, although
research is still needed. IMs promote tumor growth and me-
tastasis. Conversely, murine non-classical monocytes prevent
lung metastasis, whereas human non-classical monocytes pro-
mote angiogenesis in vitro. Since human and murine mono-
cytes have functional differences, it would be interesting to
better understand how these monocytes prevent metastasis
and to confirm that human non-classical monocytes have sim-
ilar effects on tumor metastasis. Furthermore, it would be
interesting to know the impact of non-classical monocytes
on tumor angiogenesis in vivo and to better understand mech-
anisms regulating their infiltration into tumors. The improve-
ment of the knowledge of the physiology of tumor blood
vessels and TAMs led to the development of several therapies.
Some therapy targets only TAMs with the aims to diminish
TAM survival and TAM recruitment (CCL2/CCR2 or CSF1/
CSF1R inhibition) or to induce a reprogramming of TAMs
from M2 phenotype towards M1 phenotype [208, 209]. On
the other hand, some therapies target only tumor blood vessels
and aim to inhibit angiogenesis, to improve endothelial junc-
tional integrity, to improve tumor perfusion, or to promote
vascular normalization [210]. More recently, a lot of
researches have been performed about the combination of
anti-angiogenic drugs and immunotherapies, and some of
them are currently in clinical trials (reviewed in [211, 212]).
Anti-angiogenic therapies have beneficial effects on immuno-
therapy, and inversely. More related to this review, the com-
bination of Ang-2 and VEGF inhibition induces the normali-
zation of the tumor vasculature and promotes TAM
reprogramming from M2 toward M1 phenotype and hence
increases the M1/M2 ratio and the overall survival in sarcoma
and GBM murine models [81, 213, 214]. More recently, the
dual Ang-2/VEGF inhibition has been combined with CD40
or PD-1 immune therapies and showed strong synergistic ef-
fects in terms of tumor growth, overall survival, and immune
cell activation in several murine tumor models [94, 215].
Interestingly, the combination of Ang-2/VEGF with PD-L1
or CD40 immunotherapies are currently in clinical trials
(NCT01688206; NCT02665416). In conclusion, the im-
proved knowledge in tumor-associated monocyte/
macrophage and tumor blood vessels leads to the develop-
ment of new promising and innovative therapeutic strategies
which could enhance patient overall survival. Nonetheless,
research on this topic is still needed in order to improve patient
outcome and to diminish adverse effects of the treatments.
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